期刊
CANCERS
卷 6, 期 2, 页码 969-997出版社
MDPI
DOI: 10.3390/cancers6020969
关键词
tertiary lymphoid structure; CXCL13; germinal center; anti-tumor immunity; humoral immunity; B cells; T cells
类别
资金
- Department of Defense CDMRP BCRP award [W81XWH-08-1-0570]
- Foundation of UMDNJ
- NCI Pre-doctoral Training Fellowship [5T32CA13426803]
Following the successes of monoclonal antibody immunotherapies (trastuzumab (Herceptin((R))) and rituximab (Rituxan((R)))) and the first approved cancer vaccine, Provenge((R)) (sipuleucel-T), investigations into the immune system and how it can be modified by a tumor has become an exciting and promising new field of cancer research. Dozens of clinical trials for new antibodies, cancer and adjuvant vaccines, and autologous T and dendritic cell transfers are ongoing in hopes of identifying ways to re-awaken the immune system and force an anti-tumor response. To date, however, few consistent, reproducible, or clinically-relevant effects have been shown using vaccine or autologous cell transfers due in part to the fact that the immunosuppressive mechanisms of the tumor have not been overcome. Much of the research focus has been on re-activating or priming cytotoxic T cells to recognize tumor, in some cases completely disregarding the potential roles that B cells play in immune surveillance or how a solid tumor should be treated to maximize immunogenicity. Here, we will summarize what is currently known about the induction or evasion of humoral immunity via tumor-induced cytokine/chemokine expression and how formation of tertiary lymphoid structures (TLS) within the tumor microenvironment may be used to enhance immunotherapy response.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据